<DOC>
	<DOCNO>NCT00913835</DOCNO>
	<brief_summary>The purpose study determine patient platinum-refractory platinum-resistant advanced ovarian cancer well outcome treat IMC-3G3 combination Liposomal Doxorubicin treat Liposomal Doxorubicin alone .</brief_summary>
	<brief_title>A Study Liposomal Doxorubicin With Without IMC-3G3 Platinum-refractory Resistant Advanced Ovarian Cancer</brief_title>
	<detailed_description>The primary objective study evaluate progression-free survival ( PFS ) patient platinum-refractory platinum-resistant advanced ovarian cancer treat monoclonal antibody IMC-3G3 combination liposomal doxorubicin versus liposomal doxorubicin alone .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>The patient histologically cytologically confirm epithelial ovarian cancer , primary peritoneal carcinoma , fallopian tube cancer , ovarian clear cell carcinoma The patient must least one follow : platinumfree interval ≤ 12 month final dose primary subsequent platinumbased therapy ( platinumresistant ) , progression primary subsequent Platinumbased therapy ( platinumrefractory ) , persistent radiographic disease primary subsequent platinumbased therapy ( platinumrefractory ) The patient prestudy echocardiogram multigated acquisition ( MUGA ) scan actual leave ventricular ejection fraction ( LVEF ) ≥ 50 % , within 21 day prior randomization The patient least one unidimensionally measurable target lesion ( ≥ 20 mm conventional technique , ≥ 10 mm spiral compute tomography [ CT ] magnetic resonance image [ MRI ] ) , define Response Evaluation Criteria Solid Tumors , Version 1.0 ( RECIST v 1.0 ) guideline . Tumors within previously irradiate field designate `` nontarget '' lesion unless progression document biopsy obtain confirm persistence least 90 day follow completion radiation therapy The patient recover Grade ≤ 1 National Cancer Institute Common Terminology Criteria Adverse Events , Version 3.0 ( NCICTCAE v3.0 ) effect recent surgery , radiotherapy , chemotherapy , hormonal therapy , target therapy ovarian cancer , exception alopecia peripheral neuropathy ( must resolve Grade ≤ 2 ) . The exception effect allow lab value ≤ Grade 2 specify elsewhere inclusion criterion The patient Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 1 study entry The patient ability understand willingness sign write informed consent The patient adequate hematological function ( absolute neutrophil count [ ANC ] ≥ 1200 cells/μL , hemoglobin ≥ 9 g/dL , platelet ≥ 100,000 cells/μL ) The patient adequate hepatic function define total bilirubin ≤ 1.5 × upper limit normal ( ULN ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 × ULN ( ≤ 5 × ULN presence know liver metastasis ) The patient adequate renal function define serum creatinine ≤ 1.5 × institutional ULN . If creatinine ULN , patient 's creatinine clearance ≥ 60 mL/min The patient urinary protein ≤ 1+ dipstick routine urinalysis ; urine dipstick routine analysis ≥ 2+ , 24hour urine protein must demonstrate &lt; 1000 mg protein allow participation The patient must adequate coagulation function define International Normalized Ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) ≤ 5 second ULN . Patients anticoagulation must stable dose anticoagulant therapeutic INR active bleeding within 14 day prior randomization , low molecular weight heparin AND pathological condition carry high risk bleeding . Mild elevation PTT 1.5 × ULN acceptable , provide , opinion investigator , related ongoing use coumarins ( eg , warfarin ) The patient prestudy echocardiogram multigated acquisition ( MUGA ) scan actual leave ventricular ejection fraction ( LVEF ) ≥ 50 % , within 21 day prior randomization woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior randomization duration study participation The patient brain metastasis leptomeningeal disease The patient receive one biologic and/or one hormonal therapy , administer either concomitantly platinumbased therapy separately The patient history treatment agent target PDGF PDGFR The patient increase level CA125 absence concomitant clinical radiographic progression The patient receive radiotherapy , chemotherapy , biologic therapy direct malignant tumor within 3 week prior randomization , hormonal therapy direct malignant tumor within 1 week prior randomization . Continuation hormone replacement therapy permit The patient suspect impending bowel obstruction ( include partial obstruction ) , base clinical radiographic data The patient history allergic reaction attribute compound chemical biologic composition similar IMC3G3 The patient uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic , symptomatic congestive heart failure , uncontrolled hypertension , clinically significant cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement The patient history another primary cancer , exception : ) curatively resect nonmelanomatous skin cancer ; b ) curatively treated cervical carcinoma insitu ; c ) primary solid tumor treat curative intent know active disease present treatment administer last 3 year prior randomization The patient pregnant lactate The patient ongoing side effect ≥ Grade 2 due agent administer 28 day prior randomization . The exception effect allow lab value toxicity ≤ Grade 2 , specify inclusion criterion The patient unstable angina pectoris , angioplasty , cardiac stenting , myocardial infarction 6 month prior randomization The patient participate clinical trial experimental agent within 28 day prior randomization The patient history uncontrolled hereditary acquire bleed thrombotic disorder The patient serious nonhealing active wound , ulcer , bone fracture The patient know human immunodeficiency virus positivity The patient major surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization The patient receive anthracycline indication past</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Liposomal Doxorubicin</keyword>
	<keyword>IMC-3G3</keyword>
	<keyword>3G3</keyword>
	<keyword>Platinum resistant</keyword>
	<keyword>Platinum refractory</keyword>
	<keyword>Ovary</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>PDGFr</keyword>
</DOC>